PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Alfuzosin hydrochloride - Benign prostatic hyperplasia

PAD Profile : Alfuzosin hydrochloride - Benign prostatic hyperplasia

Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Xatral

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Modified release tablets
  • Tablets
Important Information :
2nd or 3rd line. Tamsulosin MR capsules or Doxazosin immediate release tablets are preferred
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
06 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option

  • Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
  • Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)

Alfuzosin is more costly and is therefore not recommended as a 1st-line option. (NOTE - prescribe generically).

Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.01. Drugs for urinary retention
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More